2. Academic Validation
  3. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

  • Haematologica. 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011.
Stuart W Hicks 1,  Chiara Tarantelli 2,  Alan Wilhem 1,  Eugenio Gaudio 2,  Min Li 1,  Alberto J Arribas 2,  Filippo Spriano 2,  Roberta Bordone 3,  Luciano Cascione 2 4,  Katharine C Lai 1,  Qifeng Qiu 1,  Monica Taborelli 5,  Davide Rossi 2 3,  Georg Stussi 3,  Emanuele Zucca 3,  Anastasios Stathis 3,  Callum M Sloss 6,  Francesco Bertoni 7
Affiliations

Affiliations

  • 1 ImmunoGen Inc., Waltham, MA, USA.
  • 2 Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
  • 3 Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • 4 Swiss Institute of Bioinformatics, Lausanne, Switzerland and.
  • 5 Cytogenetics Laboratory, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • 6 ImmunoGen Inc., Waltham, MA, USA [email protected] [email protected].
  • 7 Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland [email protected] [email protected].
PMID: 30733273 DOI: 10.3324/haematol.2018.211011
Abstract

Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, a novel ADC based on the SAR3419 anti-CD19 antibody linked via sulfo-SPDB to the potent DNA-alkylating agent DGN462. huB4-DGN462 had improved in vitro anti-proliferative and cytotoxic activity compared to SAR3419 across multiple B-cell lymphoma and human acute lymphoblastic leukemia cell lines. In vivo experiments using lymphoma xenografts models confirmed the in vitro data. The response of B-cell lymphoma lines to huB4-DGN462 was not correlated with CD19 expression, the presence of BCL2 or MYC translocations, TP53 inactivation or lymphoma histology. In conclusion, huB4-DGN462 is an attractive candidate for clinical investigation in patients with B-cell malignancies.

Figures
Products